20 recruiting, 19 completed, 15 active not recruiting, 10 terminated. 32 Phase 2, 26 Phase 1, 8 Not applicable, 3 Early Phase 1, 1 Phase 3.
Follow Cutaneous Squamous Cell Carcinoma: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma trials Research Report on Cutaneous Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck Cemiplimab, Radiation Therapy - Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-09-01 | 2026-10-13 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Ex Vivo Cutaneous SCC ex vivo 3D ultrasonography - Cutaneous Squamous Cell Carcinoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 30 | 2026-02-01 | 2026-02-11 |
| Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Immunotherapy, Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Cutaneous Squamous Cell Carcinoma, Actinic Keratoses | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Towards Cure Via Only Ultra-short ICB in CSCC Nivolumab, Ipilumimab - Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 41 | 2025-05-14 | 2025-05-29 |
| Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma Tranexamic acid - Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Florida | 2025-05-01 | 2025-05-02 | |
| ctDNA in Cutaneous Squamous Cell Carcinoma Blood and Tissue Collection - Cutaneous Squamous Cell Carcinoma | Recruiting | Massachusetts Eye and Ear Infirmary | 60 | 2025-03-24 | 2026-03-30 | |
| Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma Ivonescimab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 24 | 2024-12-02 | 2026-06-11 |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) cemiplimab, fianlimab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Regeneron Pharmaceuticals | 2024-11-14 | 2024-07-26 | |
| Thermotherapy in Addition to SOC Palliative Radiotherapy Superficial hyperthermia - Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Recruiting | King's College London | 60 | 2024-10-14 | 2025-12-22 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Aminolevulinic acid hydrochloride 10% topical gel with Red Light - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | The Center for Clinical and Cosmetic Research | 20 | 2024-08-14 | 2024-08-29 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-06-21 | 2026-07-08 |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy Exercise Test - Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Active not recruiting | AdventHealth Translational Research Institute | 12 | 2024-06-03 | 2026-03-25 |
| B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers Immunohistochemical staining - Cutaneous Squamous Cell Carcinoma | Unknown | Sohag University | 50 | 2024-06-01 | 2024-08-06 | |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors tolododekin alfa, Cemiplimab - Advanced Solid Tumor, Cutaneous Tumor | Phase 1 | Recruiting | Ankyra Therapeutics, Inc | 97 | 2024-01-19 | 2026-03-06 |
| Dermatoscopy Guided Resection for Skin Cancer Dermatoscopy - Basal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Unknown | Region Örebro County | 400 | 2024-01-14 | 2024-04-02 |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma INCB099280 - Cutaneous Squamous Cell Carcinoma | Phase 2 | Terminated | Incyte Corporation | 63 | 2023-10-09 | 2026-10-20 |
Showing 20 of 81. Sign in to see all of them.
Skin Neoplasms (19) · Carcinoma, Merkel Cell (17) · Carcinoma, Basal Cell (16) · Squamous Cell Carcinoma of Head and Neck (16) · Carcinoma, Squamous Cell (14) · Melanoma (13) · Neoplasm Metastasis (10) · Carcinoma, Non-Small-Cell Lung (8) · Neoplasms (8) · Carcinoma, Renal Cell (6) · Head and Neck Neoplasms (6) · Carcinoma, Transitional Cell (4) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Keratosis, Actinic (4)
Neoplasms by Histologic Type (51) · Neoplasms, Glandular and Epithelial (50) · Neoplasms (49) · Carcinoma (47) · Neoplasms by Site (40) · Skin Diseases (32) · Skin and Connective Tissue Diseases (32) · Adenocarcinoma (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Neuroendocrine Tumors (20) · DNA Virus Infections (18) · Infections (18) · Tumor Virus Infections (18)
cemiplimab (15) · pembrolizumab (10) · Nivolumab (5) · Interleukin-2 (3) · Radiotherapy (3) · Cetuximab (2) · Cyclophosphamide (2) · Everolimus (2) · Fluorouracil (2) · Immunotherapy (2) · Ipilimumab (2) · Petrolatum (2) · Prednisone (2) · Sentinel Lymph Node Biopsy (2) · Sirolimus (2)
Regeneron Pharmaceuticals (7) · Maastricht University Medical Center (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Incyte Corporation (3) · Memorial Sloan Kettering Cancer Center (3) · TuHURA Biosciences, Inc. (3) · Dana-Farber Cancer Institute (2) · Massachusetts General Hospital (2) · Melanoma Institute Australia (2) · The Netherlands Cancer Institute (2) · AdventHealth Translational Research Institute (1) · Ankyra Therapeutics, Inc (1) · Baptist Health South Florida (1) · Bicara Therapeutics (1) · Centre Hospitalier Universitaire Vaudois (1)
United States (48) · Australia (14) · Canada (9) · Netherlands (9) · France (8) · Spain (6) · Belgium (5) · Germany (5) · Italy (5) · United Kingdom (5) · Poland (4) · New Zealand (3) · South Korea (3) · Brazil (2) · Denmark (2)
K Mosterd, MD, PhD (5) · Lara Dunn, MD (2) · Shadmehr Demehri, MD/PHD (2) · Ahmad Tarhini, MD, PhD (1) · Alex Mlynarek, MD (1) · Andreas Saltos, MD (1) · Andrew S Brohl, MD (1) · Ann Silk, MD (1) · Annette M Lim, MBBS, FRACP, PhD (1) · Anthony Kong (1) · Arash Yavari, MBBS (1) · Assuntina Sacco, M.D. (1) · Aung Naing, MD (1)
PMID 42580817, PMID 23026055, PMID 31951149, PMID 33477979, PMID 33989559, PMID 35276694, PMID 36094839, PMID 36821617, PMID 37055772, PMID 37848259, PMID 37865395, PMID 37875144, PMID 38252908, PMID 38758815, PMID 39797702, PMID 40178841, PMID 40230575, PMID 40454639, PMID 40577595, PMID 41022754, PMID 41062829, PMID 42102329, PMID 42476727, PMID 42558795
2019 (4), 2023 (4), P50CA254865 (1)